ARTICLE | Company News
Antares, Bio-Technology General, Ferring Pharmaceuticals deal
February 17, 2003 8:00 AM UTC
The companies ended a 1999 deal under which BTGC received exclusive rights to ANTR's needle-free injector technology for the U.S. human growth hormone market. As ended, ANTR reacquired rights for the indication. ...